Article
A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.
Targeted oncology - 1 May 2022
Salawu Abdulazeez, Hansen Aaron R, Spreafico Anna, Al-Ezzi Esmail, Webster Sheila, Bedard Philippe L, Doi Jeffrey, Wang Lisa, Siu Lillian L, Abdul Razak Albiruni R
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR)- and human epidermal growth factor receptor (HER)2-targeted therapies are approved for the treatment of breast, gastric/gastrointestinal junction (GEJ), and non-small cell lung cancer (NSCLC) with specific molecular aberrations affecting HER family members. Over 10 % of other cancers harbor genomic aberrations affecting HER family members, but their role remains...
Topics
Join the communities discussing this publication.